• Overview
  • Eligibility
  • More info
  • Locations

Phase II Clinical Evaluation of Bryostatin 1 in Patients With Hodgkin's Disease (NCT00003936)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who have recurrent or refractory Hodgkin's disease.
  • Drug: bryostatin 1
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    Accepts Healthy Volunteers
    OBJECTIVES: I. Determine the response rate in patients with recurrent or refractory Hodgkin's disease treated with bryostatin 1. II. Determine qualitative and quantitative toxicities of bryostatin 1 in these patients. III. Determine duration of response and survival in these patients.

    OUTLINE: Patients receive bryostatin 1 by continuous IV infusion over 72 hours. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity for at least 4 courses. Patients who achieve complete response (CR) are treated with 4 additional courses beyond CR.

    PROJECTED ACCRUAL: A total of 14-27 patients will be accrued for this study within 2 years.

    1 locations

    United States (1)
    • Barbara Ann Karmanos Cancer Institute
      Not specified
      Detroit, Michigan, United States, 48201
    31 May, 1999
    08 April, 2014
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!